2-(2-chloro-5-nitro-phenyl)-N-hydroxy-1H-benzoimidazole-5-carboxamidine | 886435-75-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(2-chloro-5-nitro-phenyl)-N-hydroxy-1H-benzoimidazole-5-carboxamidine
• 英文别名: 2-(2-chloro-5-nitrophenyl)-N'-hydroxy-3H-benzimidazole-5-carboximidamide
• CAS: 886435-75-2
• 化学式: C₁₄H₁₀ClN₅O₃
• 分子量: 331.718
• InChiKey: BOWLAGAWRPTXAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  133
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(2-chloro-5-nitro-phenyl)-N-hydroxy-1H-benzoimidazole-5-carboxamidine 、 正庚烷 在 盐酸 正庚烷 作用下， 以 原甲酸三乙酯 为溶剂， 反应 2.0h， 以to afford 2-(2-chloro-5-nitro-phenyl)-5-[1,2,4]oxadiazol-3-yl-1H-benzoimidazole (3.30 g, 62%)的产率得到2-(2-chloro-5-nitro-phenyl)-5-[1,2,4]oxadiazol-3-yl-1H-benzoimidazole
  参考文献：
  名称：

  Mediators of hedgehog signaling pathways, compositions and uses related hereto

  摘要：

  本发明提供了一种抑制由于刺猬增强功能、ptc失去功能或smoothened增强功能导致的异常生长状态的方法和试剂，包括将细胞与公式（I）的刺猬拮抗剂接触，以足够的量抑制异常生长状态，例如激活正常ptc通路或拮抗smoothened或刺猬活性。

  公开号：

  US08815895B2
• 作为产物：
  描述：

  2-(2-chloro-5-nitro-phenyl)-1H-benzoimidazole-5-carbonitrile 在 盐酸羟胺 、 三乙胺 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 以82%的产率得到2-(2-chloro-5-nitro-phenyl)-N-hydroxy-1H-benzoimidazole-5-carboxamidine
  参考文献：
  名称：

  WO2006/50506

  摘要：

  公开号：

文献信息

• Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals
  申请人：Sanofi-Aventis

  公开号：EP1905764A1

  公开（公告）日：2008-04-02

  The present invention relates to derivatives of 2-phenyl-benzimidazoles of the general formula (I), in which X, R, R1 to R3 and n have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及通式(I)中2-苯基-苯并咪唑衍生物，其中X、R、R1至R3和n具有声明中所示的含义，这些衍生物调节内皮一氧化氮（NO）合酶的转录，并且是有价值的药理活性化合物。具体地，通式I的化合物上调内皮一氧化氮合酶酶的表达，并可应用于需要增加该酶的表达、增加NO水平或将降低的NO水平恢复正常的情况。该发明还涉及通式I化合物的制备方法，包括它们的药物组合物，以及将通式I化合物用于制造用于促进内皮一氧化氮合酶表达或治疗各种疾病的药物，包括心血管疾病如动脉粥样硬化、血栓形成、冠状动脉疾病、高血压和心脏功能不全等。
• Mediators of Hedgehog Signaling Pathways, Compositions and Uses Related Thereto
  申请人：Guicherit Olivin M.

  公开号：US20090012082A1

  公开（公告）日：2009-01-08

  The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.

  本发明提供了用于抑制由于hedgehog增强功能、ptc失去功能或smoothened增强功能导致的异常生长状态的方法和试剂，包括将细胞与hedgehog拮抗剂（如小分子）接触，以足够的剂量抑制异常生长状态，例如，激活正常的ptc通路或拮抗smoothened或hedgehog活性。
• Substituted 2-phenyl-benzimidazoles and their use as pharmaceuticals
  申请人：ZOLLER Gerhard

  公开号：US20090239915A1

  公开（公告）日：2009-09-24

  The present invention relates to derivatives of 2-phenyl-benzimidazoles of the formula I, in which X, R, R1 to R3 and n have the meanings indicated in the claims, which modulate the transcription of endothelial nitric oxide (NO) synthase and are valuable pharmacologically active compounds. Specifically, the compounds of the formula I upregulate the expression of the enzyme endothelial NO synthase and can be applied in conditions in which an increased expression of said enzyme or an increased NO level or the normalization of a decreased NO level is desired. The invention further relates to processes for the preparation of compounds of the formula I, to pharmaceutical compositions comprising them, and to the use of compounds of the formula I for the manufacture of a medicament for the stimulation of the expression of endothelial NO synthase or for the treatment of various diseases including cardiovascular disorders such as atherosclerosis, thrombosis, coronary artery disease, hypertension and cardiac insufficiency, for example.

  本发明涉及公式I的2-苯基苯并咪唑衍生物，其中X，R，R1至R3和n具有所述权利要求中所示的含义，其调节内皮型一氧化氮(NO)合酶的转录并具有药理活性。具体而言，公式I的化合物上调内皮型NO合酶的表达，并可应用于需要增加该酶的表达或增加NO水平或正常化降低的NO水平的情况。本发明还涉及制备公式I化合物的过程，包括它们的制药组合物，以及使用公式I化合物制备用于刺激内皮型NO合酶表达或治疗各种疾病的药物，包括心血管疾病，如动脉粥样硬化，血栓形成，冠状动脉疾病，高血压和心力衰竭等。
• Mediators of hedgehog signaling pathways, compositions and uses related thereto
  申请人：Curis, Inc.

  公开号：US08168653B2

  公开（公告）日：2012-05-01

  The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.

  本发明提供了抑制因hedgehog基因增强功能、ptc基因失活功能或smoothened基因增强功能导致的异常生长状态的方法和试剂，包括将细胞与式（I）的hedgehog拮抗剂接触，以足够的剂量抑制异常生长状态，例如，激活正常的ptc通路或拮抗smoothened或hedgehog活性。
• MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED HERETO
  申请人：GUICHERIT Oivin M.

  公开号：US20120283258A1

  公开（公告）日：2012-11-08

  The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist of formula (I) in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.

  本发明提供了一种方法和试剂，用于抑制由于刺猬增益功能、ptc失活或smoothened增益功能导致的异常生长状态，包括将细胞与式(I)的刺猬拮抗剂接触，以足够的量抑制异常生长状态，例如激活正常的ptc途径或拮抗smoothened或刺猬活性。